Esketamine Hydrochloride and Tykerb

• Generic Name: esketamine
• Dosage Forms: n.a.
• Other Brand Names: Spravato

Used intranasally for treatment (in combination with an oral antidepressant) of treatment-resistant depression. Although there are various definitions of treatment-resistant depression, the condition is often defined as the failure of ≥2 trials of first-line antidepressants given in an adequate dosage for an adequate duration of therapy.

Intranasal esketamine substantially improved depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) within 24 hours of administration in a short-term clinical trial and prolonged time to relapse in a longer-term maintenance trial.

Esketamine is the S-enantiomer of racemic ketamine, which is an anesthetic agent. However, esketamine is not labeled for use as an anesthetic agent; efficacy and safety not established.

• Generic Name: lapatinib
• Dosage Forms: tablet
• Other Brand Names: Tykerb

Tykerb (lapatinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

Tykerb is used to treat a certain type of hormone-related breast cancer that has progressed or spread after treatment with other cancer medicines.

In postmenopausal women, Tykerb is given in combination with a hormonal medicine called Femara (letrozole). In others, Tykerb is given together with a cancer medicine called Xeloda (capecitabine).